Get the Stockscreener App
23.16
1.94%
0.44
After Hours:
23.16
Bicara Therapeutics Inc stock is traded at $23.16, with a volume of 486.50K.
It is up +1.94% in the last 24 hours and up +7.87% over the past month.
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa.
See More
Previous Close:
$22.72
Open:
$22.97
24h Volume:
486.50K
Relative Volume:
0.91
Market Cap:
$1.52B
Revenue:
-
Net Income/Loss:
$-137.95M
P/E Ratio:
-9.181
EPS:
-2.5226
Net Cash Flow:
$-107.11M
1W Performance:
+5.66%
1M Performance:
+7.87%
6M Performance:
+63.79%
1Y Performance:
+65.43%
1-Day Range:
$22.21
$23.19
1-Week Range:
$21.07
$23.19
52-Week Range:
$7.80
$24.25
Bicara Therapeutics Inc Stock (BCAX) Company Profile
Name
Bicara Therapeutics Inc
Sector
Industry
Phone
617-468-4219
Address
116 HUNTINGTON AVENUE SUITE 703, BOSTON
Compare BCAX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCAX
Bicara Therapeutics Inc
|
23.16 | 1.49B | 0 | -137.95M | -107.11M | -2.5226 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-25-26 | Initiated | BofA Securities | Buy |
| Jan-29-26 | Initiated | Citizens JMP | Mkt Perform |
| Jan-08-26 | Initiated | BTIG Research | Buy |
| Dec-18-25 | Initiated | Mizuho | Neutral |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| May-23-25 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Apr-17-25 | Initiated | Wells Fargo | Underweight |
| Feb-06-25 | Initiated | Wedbush | Outperform |
| Dec-06-24 | Initiated | H.C. Wainwright | Buy |
| Nov-05-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-08-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-08-24 | Initiated | Morgan Stanley | Overweight |
| Oct-08-24 | Initiated | Stifel | Buy |
| Oct-08-24 | Initiated | TD Cowen | Buy |
View All
Bicara Therapeutics Inc Stock (BCAX) Latest News
Bicara Therapeutics Chief Medical Officer Sells 5,500 Shares for $126,000 - AOL.com
Claire Mazumdar: A silent force behind a $1.6 billion firm may write Biocon's future scripts - The Economic Times
Bicara Therapeutics to Report First Quarter 2026 Financial Results and Business Updates on May 11, 2026, at 8:30 AM ET - The Manila Times
Bicara Therapeutics Inc. schedules May 11 conference for first quarter 2026 financial results - Traders Union
Bicara posts Q1 results May 11, with business update before market - Stock Titan
Insider Selling: Bicara Therapeutics (NASDAQ:BCAX) Insider Sells 5,500 Shares of Stock - MarketBeat
Bicara Therapeutics CMO David Raben sells $125,830 in shares By Investing.com - Investing.com Canada
Bicara Therapeutics CMO David Raben sells $125,830 in shares - Investing.com
Bicara Therapeutics (BCAX) CMO sells 5,500 shares after option exercise - Stock Titan
BCAX SEC FilingsBicara Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
5,500-share sale planned by BCAX (BCAX) via Form 144 on 04/27/2026 - Stock Titan
Wall Street Analysts Believe Bicara Therapeutics Inc. (BCAX) Could Rally 54.85%: Here's is How to Trade - MSN
Bicara Therapeutics (BCAX) details 2026 vote on directors and KPMG - Stock Titan
Certain Stock Option of Bicara Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 26-APR-2026. - marketscreener.com
BCAX (Bicara Therapeutics Inc.) posts narrow Q4 2025 EPS beat, shares tick higher following its quarterly earnings announcement.Social Momentum Signals - UBND thành phố Hải Phòng
Bicara Therapeutics CFO Hyep sells $211k in stock By Investing.com - Investing.com South Africa
Bicara Therapeutics CFO Hyep sells $211k in stock - Investing.com
Insider Selling: Bicara Therapeutics (NASDAQ:BCAX) CFO Sells 9,200 Shares of Stock - MarketBeat
[Form 4] Bicara Therapeutics Inc. Insider Trading Activity - Stock Titan
BCAX (BCAX) Form 144 shows option exercise and multiple insider sales - Stock Titan
Bicara Therapeutics (NASDAQ:BCAX) CEO Claire Mazumdar Sells 15,000 Shares - MarketBeat
Bicara Therapeutics CEO Mazumdar sells $354k in stock By Investing.com - Investing.com Canada
Bicara Therapeutics CEO Mazumdar sells $354k in stock - Investing.com
Bicara Therapeutics (BCAX) CEO sells 15K shares, exercises 37,760 options - Stock Titan
BCAX (BCAX) notice: 15,000 shares to be sold after option exercise - Stock Titan
Bicara Therapeutics stock hits 52-week high at 24.14 USD By Investing.com - Investing.com India
Cohlhepp Ryan, president and COO of Bicara, sells $287k in BCAX stock - Investing.com India
Bicara Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
Insider Selling: Bicara Therapeutics (NASDAQ:BCAX) COO Sells 12,500 Shares of Stock - MarketBeat
Bicara Therapeutics (BCAX) president exercises options and sells 12,500 shares - Stock Titan
Bicara Therapeutics stock hits 52-week high at 24.14 USD - Investing.com
Bicara Therapeutics Inc. (BCAX) Stock Analysis: Assessing a 27% Upside Potential for this Biotech Innovator - DirectorsTalk Interviews
Insider sales and option exercises reported for BCAX (NASDAQ: BCAX) - Stock Titan
Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Reaches New 52-Week HighTime to Buy? - MarketBeat
History Review: Is Bicara Therapeutics Incs growth already priced inOptions Play & Technical Buy Zone Confirmation - baoquankhu1.vn
CEO Moves: How liquid is Bicara Therapeutics Inc stockWeekly Risk Report & Free Reliable Trade Execution Plans - baoquankhu1.vn
BCAX PE Ratio & Valuation, Is BCAX Overvalued - Intellectia AI
Published on: 2026-04-10 20:40:14 - baoquankhu1.vn
Trading Recap: How is Bicara Therapeutics Inc managing supply chain issues2026 Retail & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
Bicara Therapeutics stock hits 52-week high at 21.99 USD By Investing.com - Investing.com Australia
Bicara Therapeutics Inc Stock (BCAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):